This preclinical study used a mouse model to show that a heterozygous MGP C19F variant causes skeletal anomalies like shorter bones and low bone mass, likely due to ER stress and impaired chondrocyte function.
Nature Communications · 12 authors, 10 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This preclinical study used a mouse model to show that a heterozygous MGP C19F variant causes skeletal anomalies like shorter bones and low bone mass, likely due to ER stress and impaired chondrocyte function.
Researchers created a mouse model (Mgp+/56G>T) carrying a human C19F variant. Analysis of 6-week-old mice revealed shorter vertebrae and long bones, craniofacial anomalies with midface retrusion, and osteopenia (reduced trabecular bone volume and number). Histology indicated poor bone remodeling with reduced osteoblast and osteoclast numbers, despite non-significant changes in mineral apposition rate. In vitro and mass spectrometry analyses suggested the variant impairs MGP signal peptide processing, leading to its accumulation in the endoplasmic reticulum. Immunofluorescence in mouse vertebrae showed increased ER stress markers (like calnexin) in chondrocytes.